These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29946047)

  • 1. A Novel Method of Serum Resistance by Escherichia coli That Causes Urosepsis.
    Coggon CF; Jiang A; Goh KGK; Henderson IR; Schembri MA; Wells TJ
    mBio; 2018 Jun; 9(3):. PubMed ID: 29946047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasion and translocation of uropathogenic Escherichia coli isolated from urosepsis and patients with community-acquired urinary tract infection.
    Owrangi B; Masters N; Kuballa A; O'Dea C; Vollmerhausen TL; Katouli M
    Eur J Clin Microbiol Infect Dis; 2018 May; 37(5):833-839. PubMed ID: 29340897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-Wide Discovery of Genes Required for Capsule Production by Uropathogenic
    Goh KGK; Phan MD; Forde BM; Chong TM; Yin WF; Chan KG; Ulett GC; Sweet MJ; Beatson SA; Schembri MA
    mBio; 2017 Oct; 8(5):. PubMed ID: 29066548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Characterization of the Vacuolating Autotransporter Toxin in Uropathogenic Escherichia coli.
    Nichols KB; Totsika M; Moriel DG; Lo AW; Yang J; Wurpel DJ; Rossiter AE; Strugnell RA; Henderson IR; Ulett GC; Beatson SA; Schembri MA
    J Bacteriol; 2016 May; 198(10):1487-98. PubMed ID: 26858103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptidoglycan Association of Murein Lipoprotein Is Required for KpsD-Dependent Group 2 Capsular Polysaccharide Expression and Serum Resistance in a Uropathogenic
    Diao J; Bouwman C; Yan D; Kang J; Katakam AK; Liu P; Pantua H; Abbas AR; Nickerson NN; Austin C; Reichelt M; Sandoval W; Xu M; Whitfield C; Kapadia SB
    mBio; 2017 May; 8(3):. PubMed ID: 28536290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and Structural Characterization of a Novel Escherichia coli Interleukin Receptor Mimic Protein.
    Moriel DG; Heras B; Paxman JJ; Lo AW; Tan L; Sullivan MJ; Dando SJ; Beatson SA; Ulett GC; Schembri MA
    mBio; 2016 Mar; 7(2):e02046. PubMed ID: 26980835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.
    Habibi M; Asadi Karam MR; Bouzari S
    Microb Pathog; 2017 Sep; 110():477-483. PubMed ID: 28754265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens.
    Sarkissian CA; Alteri CJ; Mobley HLT
    Vaccine; 2019 Aug; 37(35):4937-4946. PubMed ID: 31320216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection.
    Brumbaugh AR; Smith SN; Mobley HL
    Infect Immun; 2013 Sep; 81(9):3309-16. PubMed ID: 23798537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virulence factors of uropathogenic Escherichia coli (UPEC) and correlation with antimicrobial resistance.
    Shah C; Baral R; Bartaula B; Shrestha LB
    BMC Microbiol; 2019 Sep; 19(1):204. PubMed ID: 31477018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing.
    Wells TJ; Whitters D; Sevastsyanovich YR; Heath JN; Pravin J; Goodall M; Browning DF; O'Shea MK; Cranston A; De Soyza A; Cunningham AF; MacLennan CA; Henderson IR; Stockley RA
    J Exp Med; 2014 Aug; 211(9):1893-904. PubMed ID: 25113975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-LPS IgA and IgG Can Inhibit Serum Killing of Pseudomonas aeruginosa in Patients with Cystic Fibrosis.
    Pham A; Ledger EL; Coggon CF; Henderson IR; Reid DW; Bell SC; Smith DJ; Wells TJ
    Infect Immun; 2021 Nov; 89(12):e0041221. PubMed ID: 34460286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Requirements of Escherichia coli in Intracellular Bacterial Communities during Urinary Tract Infection Pathogenesis.
    Conover MS; Hadjifrangiskou M; Palermo JJ; Hibbing ME; Dodson KW; Hultgren SJ
    mBio; 2016 Apr; 7(2):e00104-16. PubMed ID: 27073089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virulence properties of uropathogenic Escherichia coli isolated from children with urinary tract infection in Korea.
    Kim DH; Subhadra B; Kang HY; Woo K; Kim J; Son YJ; Sohn KM; Kim HJ; Han K; Oh MH; Choi CH
    Genes Genomics; 2018 Jun; 40(6):625-634. PubMed ID: 29892947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of acute urinary tract infections caused by uropathogenic
    Pullanhi U; Khan S; Vinod V; Mohan K; Kumar A
    Ann Afr Med; 2019; 18(3):138-142. PubMed ID: 31417014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uropathogenic Escherichia coli strains harboring tosA gene were associated to high virulence genes and a multidrug-resistant profile.
    Xicohtencatl-Cortes J; Cruz-Córdova A; Cázares-Domínguez V; Escalona-Venegas G; Zavala-Vega S; Arellano-Galindo J; Romo-Castillo M; Hernández-Castro R; Ochoa SA; Luna-Pineda VM
    Microb Pathog; 2019 Sep; 134():103593. PubMed ID: 31195111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine SIGNR1 (CD209b) Contributes to the Clearance of Uropathogenic
    Zhang Y; Zhang S; He Y; Sun Z; Cai W; Lv Y; Jiang L; Li Q; Zhu S; Li W; Ye C; Wu B; Xue Y; Chen H; Cai H; Chen T
    Front Cell Infect Microbiol; 2019; 9():457. PubMed ID: 31998663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli.
    Asadi Karam MR; Habibi M; Bouzari S
    Mol Immunol; 2019 Apr; 108():56-67. PubMed ID: 30784763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengths and Limitations of Model Systems for the Study of Urinary Tract Infections and Related Pathologies.
    Barber AE; Norton JP; Wiles TJ; Mulvey MA
    Microbiol Mol Biol Rev; 2016 Jun; 80(2):351-67. PubMed ID: 26935136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli.
    Smith MA; Weingarten RA; Russo LM; Ventura CL; O'Brien AD
    Infect Immun; 2015 Apr; 83(4):1661-73. PubMed ID: 25667267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.